Skip to content

Study · Randomized controlled trial · n = 31 · 2016

6 results

Unaltered Oxytocin and Vasopressin Plasma Levels in Patients with Schizophrenia After 4 Months of Daily Treatment with Intranasal Oxytocin.

Busnelli M, Dagani J, de Girolamo G, Balestrieri M, Pini S, Saviotti FM, Scocco P, Sisti D, Rocchi M, Chini B

Journal of neuroendocrinology1 Apr 2016Cited by 11 (Europe PMC)

PMID26715485 (opens in a new tab)DOI10.1111/jne.12359 (opens in a new tab)PepBankPUB-26715485
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In patients with schizophrenia, 4 months of daily intranasal oxytocin did not change plasma oxytocin concentration from baseline, compared with placebo.

    In plain wordsIn people with schizophrenia, 4 months of daily nasal oxytocin did not change their blood oxytocin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma oxytocin concentration
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    40 IU · intranasal · 4 monthsAs given in this study (human).

    Measurements

    baseline plasma OXT
    1.62 pg/ml
    baseline

    Source sentences

    Summary
    Our data indicate a mean ± SD baseline OXT concentration of 1.62 ± 0.68 pg/ml, as determined by radioimmunoassay, which did not display any significant variation after chronic treatment with OXT or placebo.
    1 context sentence
    Summary · context
    In the present study, in a within-subjects cross-over, double-blind, randomised controlled trial, we assayed the plasma levels of OXT and AVP in 31 patients with schizophrenia who were treated daily for 4 months with 40 IU of intranasal OXT or placebo.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with schizophrenia, 4 months of daily intranasal oxytocin left plasma osmolality stable.

    In plain wordsIn people with schizophrenia, 4 months of daily nasal oxytocin did not change blood osmolality.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma osmolality
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    40 IU · intranasal · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    The present study also assessed cardiovascular and body fluid indicators (osmolality, plasma sodium concentration and systolic blood pressure), as well as a parameter for food intake (body mass index), with all observed to remain stable.
    1 context sentence
    Summary · context
    In the present study, in a within-subjects cross-over, double-blind, randomised controlled trial, we assayed the plasma levels of OXT and AVP in 31 patients with schizophrenia who were treated daily for 4 months with 40 IU of intranasal OXT or placebo.
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with schizophrenia, 4 months of daily intranasal oxytocin left plasma sodium concentration stable.

    In plain wordsIn people with schizophrenia, 4 months of daily nasal oxytocin did not change blood sodium levels.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma sodium concentration
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    40 IU · intranasal · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    The present study also assessed cardiovascular and body fluid indicators (osmolality, plasma sodium concentration and systolic blood pressure), as well as a parameter for food intake (body mass index), with all observed to remain stable.
    1 context sentence
    Summary · context
    In the present study, in a within-subjects cross-over, double-blind, randomised controlled trial, we assayed the plasma levels of OXT and AVP in 31 patients with schizophrenia who were treated daily for 4 months with 40 IU of intranasal OXT or placebo.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with schizophrenia, 4 months of daily intranasal oxytocin left systolic blood pressure stable.

    In plain wordsIn people with schizophrenia, 4 months of daily nasal oxytocin did not change systolic blood pressure.

    Peptide
    Oxytocin
    Outcome
    No significant changeSystolic blood pressure
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    40 IU · intranasal · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    The present study also assessed cardiovascular and body fluid indicators (osmolality, plasma sodium concentration and systolic blood pressure), as well as a parameter for food intake (body mass index), with all observed to remain stable.
    1 context sentence
    Summary · context
    In the present study, in a within-subjects cross-over, double-blind, randomised controlled trial, we assayed the plasma levels of OXT and AVP in 31 patients with schizophrenia who were treated daily for 4 months with 40 IU of intranasal OXT or placebo.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with schizophrenia, 4 months of daily intranasal oxytocin left body mass index, used as a food intake parameter, stable.

    In plain wordsIn people with schizophrenia, 4 months of daily nasal oxytocin did not change body mass index.

    Peptide
    Oxytocin
    Outcome
    No significant changeBody mass index
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    40 IU · intranasal · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    The present study also assessed cardiovascular and body fluid indicators (osmolality, plasma sodium concentration and systolic blood pressure), as well as a parameter for food intake (body mass index), with all observed to remain stable.
    1 context sentence
    Summary · context
    In the present study, in a within-subjects cross-over, double-blind, randomised controlled trial, we assayed the plasma levels of OXT and AVP in 31 patients with schizophrenia who were treated daily for 4 months with 40 IU of intranasal OXT or placebo.
  6. 06HumanRandomized controlled trialMechanism

    In patients with schizophrenia, plasma arginine vasopressin stayed unchanged during 4 months of daily intranasal oxytocin or placebo.

    In plain wordsIn people with schizophrenia, 4 months of daily nasal oxytocin did not change blood levels of the related hormone vasopressin.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma arginine vasopressin concentration
    Study

    n = 31

    Comparator
    Placebo
    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    40 IU · intranasal · 4 monthsAs given in this study (human).

    Measurements

    baseline plasma AVP
    2.4 pg/ml
    baseline

    Source sentences

    Summary
    Similarly, the mean ± SD baseline AVP value of 2.40 ± 1.26 pg/ml remained unchanged.
    1 context sentence
    Summary · context
    In the present study, in a within-subjects cross-over, double-blind, randomised controlled trial, we assayed the plasma levels of OXT and AVP in 31 patients with schizophrenia who were treated daily for 4 months with 40 IU of intranasal OXT or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.